CD33 and acute myeloid leukemia: A comparison of CD302 to CD33 gene expression in a published cohort of 460 AML patients [13] demonstrated high expression of the former across FAB disease subtypes (highest on M4-M5) and a moderate positive correlation of expression between the markers (r = 0.4749, p<0.0001; panels A-B of S2 Fig).